Share

Related Stories

  • Most downloaded review Q1 2009: Target discovery from data mining approaches
    The most downloaded review article from Drug Discovery Today from the first quarter of 2009 deals with the topic of target discovery from the informatics perspective. It would be difficult to overstate the value to Pharma of identifying and validating the most relevant therapeutic targets. In this article, Yang, Adelstein and Kassis outline text mining, its value and limitations and application to target discovery. In addition, they cover the field of emerging and integrated data mining approaches.
  • Together we will beat cancer
    Despite the doom and gloom surrounding the pharmaceutical industry and the many commentaries highlighting inefficiencies of the sectors operating model, 2011 has proven to be a near-record year for approvals of innovative new drugs. These approvals include seven new cancer treatments with two of these (Pfizer’s crizotinib, Xalkori™ and Roche’s vemurafenib, Zelboraf™) made in conjunction with companion genetic tests, reinforcing the notion that the practice of stratified medicine has truly arrived. The forthcoming special issue of Drug Discovery Today on cancer highlights innovative contributions in basic, translational and clinical research made by UK scientists and clinicians in the fight against cancer.
  • Babraham scientists reveal how white blood cells get activated in auto-immune disease, helping to target better drugs for these disorders
    Scientists at the Babraham Institute have discovered a critical piece of the jigsaw that explains how a type of immune cell – a white blood cell known as a neutrophil – is activated by antibodies. The research, published today in the journal Science Signaling, brings new understanding to how the Phosphatidylinositol 3-kinase (PI3K) signalling pathway is used to regulate neutrophil function. This may pave the way for the development of a strategy to specifically inhibit the inappropriate activation of these immune cells that is seen in auto-immune inflammatory conditions such as rheumatoid arthritis, glomerulonephritis and some skin blistering diseases.
  • The long term cost of inferior database quality
    This month’s editorial is written by Antony J. Williams and Sean Ekins. “If I have seen further than others, it is by standing upon the shoulders of giants.”Isaac Newton
  • Cellular Feast or Famine
    Study shows how cells decide whether they have enough fat – a molecular checkpoint that, when disturbed, could lead to obesity or other diseases.

Top 5 Stories

News

Anti-inflammatory signal protein discovered

19 February 2010

Researchers have discovered a protein crucial in mediating the anti-inflammatory actions of nuclear lipid receptors. The findings create new possibilities for treating metabolic diseases associated with inflammation, such as diabetes.

A team led by Professor Eckardt Treuter at the Karolinska Institutet has investigated the molecular mechanisms of how the nuclear lipid receptors LRH-1 and LXR inhibit inflammatory gene expression in liver during the so-called ‘acute phase response’.

The study identified GPS2, a protein that directly interacts with receptors, as a central component of a sophisticated protein network – or ‘genomic positioning system’ – determining where and when these lipid receptors can function anti-inflammatory.

The identified pathway connects metabolism and inflammation and, therefore, is relevant for the understanding of metabolic diseases, such as diabetes and atherosclerosis. The researchers suspect even broader roles of related pathways in different tissues linked to metabolic diseases and to cancers.

‘We are now closer to understanding, at the molecular level, how dysregulation of individual components of these pathways causes alterations in gene expression that contribute to the development of metabolic diseases linked to inflammation,’ states Professor Treuter. ‘This knowledge may open up novel pharmacological interventions. For example, drugs that stabilize receptor interactions with GPS2 could possibly trigger the anti-inflammatory pathway.’

Nuclear receptors are regulatory proteins within the cell nucleus that can bind directly to a variety of hormones, metabolites and pharmaceuticals. Binding affects the activity of these proteins, causing them to switch genes on or off, which, in turn, leads to increased or decreased production of the proteins that carry out diverse functions within the cell.

Numerous nuclear receptors are known as master regulators of lipid metabolism and homeostasis. Latest research indicates that these receptors also have important roles in the control of inflammation via mechanisms that have yet to be clarified.

Further reading

Venteclef, N. et al. (2010) GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRb in the hepatic acute phase response. Genes & Development 24, 381–395

 

This article is featured in:
Target Identification/ Validation

 

Comment on this article

You must be registered and logged in to leave a comment about this article.